Comment Letters
Comment Letters
Biocom California is actively engaged in submitting comments to federal health agencies on draft guidances and proposals. We monitor and engage in important regulatory and reimbursement matters on behalf of the California life science community.
Biocom California Comment Letters
-
Biocom California March-In Rights Letter – May 17, 2022
Download -
Extension of SBIR/STTR Programs Letter – May 9, 2022
Download -
Biocom California FY23 FDA Appropriations Letter – May 4, 2022
Download -
Biocom California FY23 Labor & HHS Appropriations Letter – May 4, 2022
Download -
Biocom California FY23 MilCon VA Appropriations Letter – May 4, 2022
Download -
Biocom California OSTP RFI Response – March 31, 2022
Download -
Medical Devices EUA Transition Plan Comment Letter – March 23, 2022
Download -
Multi-State MedTech R&D Expensing Letter – March 21, 2022
Download -
Multi-State QSBS Letter – March 18, 2022
Download -
Biocom California’s Response to the Health Future Task Force’s RFI on Wearable Technologies – March 4, 2022
Download -
Biocom California “March-In” Comment Letter
Download -
Comments on National Coverage Analysis (NCA) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease – February 11, 2022
Download -
Protect the Orphan Drug Tax Credit – February 4, 2022
Download -
Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial – December 21, 2021
Download -
Medtech Associations Letter Regarding Semiconductor Shortage – November 19, 2021
Download -
Comments on Medicare Coverage of Innovative Technology (MCIT) Pathway Removal – October 15, 2021
Download -
Comments on FDA Remanufacturing Guidance – September 22, 2021
Download -
Comments in Response to PFS FY22 – September 13, 2021
Download -
Response to the Cures 2.0 Discussion Draft – July 16, 2021
Download
Sign up for our newsletter
Customize your newsletter subscription to receive only the newsletters that are relevant to you.